Table 2.

Sustained virological response (SVR) in hepatitis C virus-G1 according to racial factors

References	Race	Number of patients	Naïve	Formula of therapy	Duration of treatment (weeks)	SVR (%)
Liu et al. [17]	Asian (Taiwan)	308	Yes	PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	76
				PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	24	56
Yamada et al. [100]	Asians (Japan)	192	Yes	PegIFN-α-2a 180 μg/week + RBV 600–1,000 mg/day	48	59.4
				PegIFN-α-2a 180 μg/week + placebo	48	24.0
Muir et al. [16]	Blacks	100		PegIFN-α-2b 1.5 μg/kg per week + RBV 800–1,000 mg/day 48	19
	Non-Hispanic Whites	100		PegIFN-α-2b 1.5 μg/kg per week + RBV 800–1,000 mg/day 48	52
Rodriguez-Torres et al. [15]	Latino	269	Yes	PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	34
	Non-Latino	300	Yes	PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	49
Hepburn et al. [14]	Asians	36		IFN + RBV	48	61
	Whites	496				39
	Hispanics	79				23
	African-Americans	50				14
Conjeevaram et al. [13]	African-Americans	19	Yes	PegIFN-α-2a 180 μg/week + RBV 1,000–1,200 mg/day	48	28
	Caucasian Americans	20				52

Naïve treatment-naïve